Syngene International Ltd Q4 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/ewygf95p025hk9t23rjziw4t.pdf

Key Takeaways


FY26 Guidance: The Two-Speed Story

Deepak Jain: "As we bring the new biologics manufacturing facilities into operations, the additional operating costs and depreciation will impact margins. With this, we expect EBITDA margin to moderate from current levels to the mid-twenties and year-on-year decline in profit after tax."

The US Biologics Bet


FY25 Full-Year: Resilience in a Divided Year


Q4 FY25: The Milestone Quarter

Peter Bains: "Syngene reported revenue growth of 11% year-on-year, and 8% sequentially crossing the Rs. 1,000 Cr in a quarter threshold for the first time. At the EBITDA level growth was 9% year-on-year reflecting good underlying fundamentals. The highlight of the quarter was the acquisition of a state-of-the-art biologics manufacturing facility in the US, strengthening Syngene's position in the fast-growing biologics CDMO sector and providing a strategic foothold in the US market."

Operational Initiatives and Technology


Guidance & Commitments

CommitmentSpecificsTimeline
Underlying revenue growthEarly teens growth, broad-based across research, development and manufacturingFY26
Reported revenue growthMid-single digit, adjusted for client-level inventory balancing in large molecule commercial manufacturingFY26
EBITDA marginModerate to mid-twenties from ~34% in Q4 FY25FY26
Profit after taxYear-on-year declineFY26
Business momentumPipeline build in small and large molecules, supported by new pilot programs and conversion of existing pilots in discovery servicesFY26

Key Metrics

MetricQ4 FY25
Revenue from operations₹1,018 Cr, up 11% YoY and 8% QoQ
Reported revenue₹1,037 Cr, up 11% YoY
Operating EBITDA₹363 Cr, up 9% YoY
Operating EBITDA margin35.0%, vs 35.7% in Q4 FY24
Reported PAT (before exceptional items)₹183 Cr, down 3% YoY
Reported PAT margin17.7%, vs 20.2% in Q4 FY24
FY25 revenue from operations₹3,642 Cr, up 4% YoY
FY25 constant currency revenue growth2%
FY25 operating EBITDA margin29%
FY25 PAT before exceptional items₹475 Cr, down 8% YoY
FY25 PAT after exceptional item₹496 Cr, down 3% YoY
FY26 revenue growth guidance (underlying)early teens
FY26 reported revenue growth guidancemid-single digit, adjusted for client inventory balancing in large molecule commercial manufacturing
FY26 EBITDA margin guidancemid-twenties, moderating from current levels due to new biologics facility costs and depreciation
Total single-use bioreactor capacity50,000L, post US biologics facility acquisition
Final dividend per share (FY25)₹1.25, recommended, subject to shareholder approval
Cash and cash equivalents367.1 crore as of 31 March 2025, vs 85.7 crore as of 31 March 2024
Net cash positionimproved